Basic Coracten Information

• INN (International Nonproprietary Name): Nifedipine
• Brand Names Available In United Kingdom: Adalat, Adalat CC, and generic nifedipine ER formulations are commonly listed; other international brands include Procardia XL and Afeditab CR but availability varies by supplier and pack[see product information]
• ATC Code: C08CA05
• Forms & Dosages: Extended‑release tablets 30 mg, 60 mg, 90 mg; immediate‑release 10 mg and 20 mg (less common); modified‑release 20 mg, 30 mg, 60 mg
• Manufacturers In United Kingdom: Original brand Bayer AG (Germany) and common generic manufacturers include Teva, Sandoz/Novartis, Mylan, Actavis, Apotex; local suppliers may vary
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription‑only medicine (POM)

Critical Warnings, Restrictions And Immediate Patient Protection

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Nifedipine can cause symptomatic hypotension, reflex tachycardia and peripheral oedema which may be severe when started or if dose is changed suddenly.

Patients must not self‑start, stop suddenly or adjust the dose without a clinician’s advice because abrupt changes can worsen angina or cause dangerous low blood pressure.

Pregnant or breastfeeding people should avoid nifedipine unless a specialist recommends it and documents the rationale, because pregnancy and lactation require specialist assessment.

Frail elderly patients need extra caution; start at a lower dose and monitor blood pressure and heart rate closely to reduce fall and syncope risk.

Severe hepatic impairment requires dose reduction and close monitoring since nifedipine is metabolised in the liver.

Recent myocardial infarction (within about two weeks) or cardiogenic shock are contraindications to nifedipine use.

Children require specialist dosing and supervision; paediatric use is specialist and usually weight‑based.

Classification: INN = Nifedipine; ATC = C08CA05; classification = prescription‑only medicine.

Contact your GP, NHS 111, or local pharmacist immediately for acute adverse effects such as chest pain, severe dizziness or fainting.

• Immediate Red Flags: severe hypotension (very low BP), syncope (fainting), new or worsening chest pain.
• Actions: stop the drug if advised by a clinician, seek urgent assessment via 999 or A&E for chest pain, use NHS 111 for urgent advice about dizziness or collapse.

Carry this checklist with you when travelling, attending appointments or starting a new prescription:

• Medicine name and strength (e.g., Coracten/Adalat/Nifedipine)
• Start date and prescribing clinician
• Emergency contact and known allergies
• Recent BP and heart rate readings

Report suspected adverse reactions to the MHRA Yellow Card scheme and include the medicine name and brand (for example Coracten, Adalat or generic nifedipine) and batch if known.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Nifedipine may impair alertness, especially when treatment is started or after dose increases.

UK drivers must assess their fitness to drive and must not drive if a side effect affects driving ability; notify the DVLA only if a condition or medication side effect affects driving as required by guidance.

Avoid driving, operating heavy machinery or working at height until you know how you react to nifedipine.

• Common impairing effects: dizziness, visual blurring, syncope (fainting).
• Workplace adjustments: task reassignment away from driving or machinery, phased return to duties, temporary restriction from safety‑critical roles.

Employers should follow HSE guidance on fitness for work and reasonable adjustments where a medication may affect safety at work.

Ask your pharmacist for a counselling note and keep a simple record of dosing times to help reduce risk at work and to show to an occupational health adviser if required.

Q&A — “Can I Drive After Taking It In The UK?”

Q: Can I drive after taking nifedipine/Coracten?

A: Not until you know it does not make you dizzy or faint.

If you experience dizziness, fainting or blurred vision you must not drive and should seek clinical advice.

Report persistent impairing symptoms to your GP and follow DVLA guidance if advised.

Usage Basics: Names, Classification And UK Availability

INN, Brand Names Available In The UK

Coracten is used internationally as a brand name; the active substance is nifedipine (INN).

The ATC code is C08CA05 and nifedipine is a dihydropyridine calcium‑channel blocker indicated for hypertension and angina pectoris.

Common brands and generics seen in the market include Adalat and generic nifedipine ER; packs are often labelled as Nifedipine ER or Adalat in local language.

• INN → Nifedipine
• ATC → C08CA05
• Common brands → Adalat, Coracten, generics (Nifedipine ER)

Common formulations include extended‑release tablets 30 mg, 60 mg and 90 mg, and immediate‑release 10 mg–20 mg which are less commonly used for outpatient chronic therapy.

Always check the SPC and PIL supplied with each pack and consult your GP or NHS pharmacist for product‑specific advice.

Legal Classification (POM, P, GSL) And Prescribing Context

Nifedipine/Coracten is prescription‑only (POM) across the United Kingdom and must be prescribed by an authorised prescriber and dispensed via community or hospital pharmacies.

NHS prescribing pathways include electronic prescriptions (EPS), repeats issued by GP surgeries and specialist supplies from hospital cardiology clinics.

Check MHRA guidance and local NHS formularies for product specifics and any supply restrictions in your area.

Dosing Guide (Practical NHS‑Aligned Regimens)

Standard Regimens And Titration

Typical starting dose for hypertension or chronic stable angina is an extended‑release 30 mg once daily.

Maintenance commonly ranges from 60 mg to 90 mg once daily as tolerated, with a typical maximum daily dose of 90 mg for ER formulations.

Immediate‑release 10–20 mg preparations are less commonly used for outpatient blood pressure control because of safety concerns.

• Monitor blood pressure and heart rate within 1–2 weeks after starting or after dose changes.
• Watch for ankle swelling, increasing shortness of breath, marked dizziness or palpitations.

Adjustments For Comorbidities And Special Populations

Reduce dose in hepatic impairment and monitor liver function tests where indicated because nifedipine is metabolised hepatically.

Start elderly patients at a lower dose and titrate slowly because of an increased risk of hypotension and falls.

Children should only be treated by paediatric specialists using weight‑based dosing; typical paediatric starting ranges are 0.25–0.5 mg/kg/day in divided doses for specialist indications.

When combining nifedipine with other antihypertensives, anticipate additive hypotension and monitor more closely.

In patients with heart failure or severe aortic stenosis, seek cardiology input before initiating nifedipine.

Q&A — “What If I Miss A Dose?”

Q: Missed dose advice?

A: Take the missed dose as soon as you remember unless it is near the next scheduled dose; do not double up.

If unsure, contact NHS 111 or your pharmacist for tailored advice.

Interaction Chart: Drugs, Foods And Clinically Important Interactions

Food And Drink Interactions

Alcohol may potentiate hypotension and dizziness when taken with nifedipine.

Caffeine from coffee or green tea has minimal direct pharmacokinetic interaction but can affect blood pressure variability.

Grapefruit juice inhibits CYP3A4 and may alter nifedipine metabolism, so avoid or limit grapefruit and grapefruit products while taking nifedipine.

• Avoid or limit: grapefruit juice, binge alcohol consumption.
• Discuss dietary habits at counselling to reduce risk of interactions.

Drug Interactions And MHRA‑Relevant Warnings

Strong CYP3A4 inducers such as rifampin reduce nifedipine concentrations and may reduce efficacy; concurrent rifampin use is listed as a contraindication in some product information.

Strong CYP3A4 inhibitors such as certain azole antifungals and some macrolide antibiotics can increase nifedipine levels and raise the risk of hypotension.

Additive hypotension can occur with other antihypertensives, nitrates or alcohol and increases the risk of syncope.

Encourage MHRA Yellow Card reporting for suspected interactions or adverse reactions and increased monitoring when co‑prescribing high‑risk medicines.

User Reports & Trends (UK Patient Experience Snapshot)

Patients on NHS.uk, Patient.info and forum discussions frequently report that ER formulations reduce fluctuation in symptoms compared with immediate‑release products.

Common early side effects include headache, flushing and ankle swelling, and many users are concerned about faintness or interactions with other medicines.

• Common praise: effective blood pressure reduction and fewer angina episodes on ER formulations.
• Common concerns: ankle swelling, dizziness on standing, and questions about drug interactions.

Pharmacist counselling improves adherence and reduces worry about side effects and dosing times.

Use patient reports critically and prioritise SPC, PIL and professional advice over forum suggestions.

Access & Purchase Options In The UK

High‑Street Chains: Boots, LloydsPharmacy, Superdrug

Patients obtain nifedipine on NHS prescription dispensed at Boots, LloydsPharmacy, Superdrug or a local independent pharmacy.

Private prescriptions are accepted at these chains and pharmacists can provide counselling and liaise with prescribers for repeats or interaction checks.

• Bring: valid prescription, up‑to‑date list of medicines and allergy history.
• Ask the pharmacist for a written record of dosing times and monitoring appointments.

Online Pharmacies And NHS E‑Prescriptions — Safety Checklist

Registered UK online pharmacies operate under MHRA and GPhC jurisdiction and offer NHS and private dispensing.

Validate legitimacy by checking the GPhC register and NHS.uk links before ordering medicines online.

Checklist for online ordering: prescription required, avoid overseas suppliers without UK regulation, keep labels and PIL for your records.

In our online pharmacy, coracten is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Mechanism Of Action & Pharmacology (Clear, Patient‑Friendly)

Simple Explanation For Patients

Nifedipine is a dihydropyridine calcium‑channel blocker that relaxes the smooth muscle in blood vessel walls.

By widening the vessels it lowers peripheral resistance and reduces blood pressure, and it lowers the heart’s workload which helps prevent angina.

Think of it as widening the pipes that carry blood so the heart can pump more easily and blood pressure falls.

• Vasodilation: blood vessels widen.
• Peripheral resistance: the force against which the heart pumps is reduced.
• ER vs Immediate‑Release: ER gives steadier blood levels; immediate‑release acts faster but can cause rapid BP drops.

Clinical Terms And What To Monitor

Monitor seated and standing blood pressure and heart rate to detect symptomatic hypotension or reflex tachycardia.

Watch for increasing breathlessness or swelling that could indicate worsening heart failure.

ER formulations produce steadier plasma levels; immediate‑release has faster onset and a higher risk of reflex effects.

• Monitoring schedule: baseline, 1–2 weeks after start or dose change, and periodic review thereafter.
• Consider home BP monitoring for patients with labile readings or at higher fall risk.

Indications & Off‑Label Uses (MHRA Context)

MHRA‑Approved Indications

Nifedipine is indicated for treatment of hypertension and angina pectoris including stable and vasospastic angina.

Off‑Label Practice In NHS/Private Care

Off‑label uses include certain paediatric indications or post‑transplant hypertension under specialist supervision.

Immediate‑release nifedipine for acute blood pressure lowering is generally avoided outside hospital due to safety concerns.

• Examples of off‑label use: specialist paediatric hypertension management, transplant hypertension.
• Safeguards: documented clinician rationale, informed consent and specialist review.

Key Clinical Findings (UK/EU Evidence Summary Up To 2025)

Extended‑release nifedipine is effective for chronic hypertension and reduces frequency of angina episodes in stable disease.

Immediate‑release forms have historically been associated with abrupt blood pressure falls and adverse cardiac events when misused, so ER products are favoured for outpatient treatment.

UK and EU meta‑analyses through recent years underscore careful patient selection and monitoring when prescribing dihydropyridine CCBs.

• Main findings: ER nifedipine provides smoother BP control and is better tolerated than immediate‑release in chronic use.
• Clinical recommendation: consult NICE, British Hypertension Society and cardiology guidance for up‑to‑date practice.

Alternatives Matrix (NHS Prescribing Alternatives)

Comparison Table (Suggested Table)

Pros & Cons Checklist For Switching From Nifedipine (Coracten)

• Reason to switch: intolerable side effects, drug interactions, or formulary preference.
• Monitor closely for hypotension or increased angina in the first 1–2 weeks after switch.
• Inform employer/driver if symptoms change; update GP record and medication list.
• Contact pharmacist for dose equivalence guidance and counselling.
• Red flags requiring urgent review after switch: syncope, chest pain, marked hypotension.

Common Questions From UK Patients (Concise Answers)

• Is Coracten safe long‑term? — Yes when monitored; do not stop suddenly without clinician advice.
• Can it cause weight gain? — Peripheral oedema may mimic weight gain; report swelling to your clinician.
• Can I drink alcohol? — Limit alcohol to reduce hypotension risk.
• Will it interact with my antidepressant/antifungal? — Some antidepressants and antifungals can interact; always check with a pharmacist.
• What about stopping it? — Do not stop abruptly; taper only under clinician direction.

Contact your GP or pharmacist for personalised checks and interaction reviews.

NHS Cost & Access Comparison

Private pharmacy costs for a 30‑day supply of generic ER nifedipine vary; check local pharmacies and consider prescription prepayment certificates or the NHS Low Income Scheme if eligible.

Registration, Regulation And Reporting (MHRA & NHS Framework)

MHRA Approval And Pharmacovigilance

Nifedipine products are regulated by the MHRA and clinicians should check the SPC and PIL for the product being prescribed or dispensed.

Report suspected adverse reactions via the MHRA Yellow Card scheme and include brand and batch where possible.

• Prescriber checklist: review SPC, confirm dose, check interactions and set a monitoring plan.

NHS Prescribing Framework And Electronic Records

Record indication, start date, formulation and monitoring plan in the GP record and issue EPS for repeats where appropriate.

Include templated follow‑up reminders such as a blood pressure check at 1–2 weeks after initiation or dose change.

Provide the patient with the PIL and document counselling in the record.

Storage, Transport And Domestic Handling

UK Household Storage Guidance

Store nifedipine between 20–25°C, protected from light and moisture and keep tablets in the original packaging until use.

Avoid storing medicines in bathrooms or other damp areas in UK homes.

Always keep medicines out of reach of children and pets.

Travel checklist: carry medicines in hand luggage, keep a copy of the prescription and maintain cool temperatures where possible.

Handling During Supply And Disposal

Return unused tablets to a pharmacy for safe disposal; do not flush down the toilet or sink.

Label multi‑dose boxes with the patient’s name and dosing schedule for clarity.

• Pharmacists should counsel on storage, what to do if a tablet is overheated or frozen, and advise safe disposal routes.

Guidelines For Proper Use And Pharmacist Counselling Style

Key Counselling Points For UK Pharmacists

Confirm the indication, dose and formulation and check for contraindications such as recent MI or cardiogenic shock.

Advise on side‑effect recognition including headache, flushing, ankle swelling and dizziness.

Discuss driving and work implications and perform interaction checks including rifampin and grapefruit avoidance.

Provide the patient with the PIL and a written checklist covering emergency symptoms, monitoring appointments and contact details.

NHS Patient Safety Advice And Follow‑Up Schedule

Recommend blood pressure and heart rate checks at baseline and 1–2 weeks after initiation or dose change, then review at 6–12 weeks and periodically thereafter.

For vulnerable patients arrange closer follow‑up and consider home blood pressure monitoring.

• Clinician checklist: baseline BP/HR and relevant blood tests, follow‑up at 1–2 weeks, refer to cardiology if concerning symptoms occur.

Delivery Across United Kingdom

Final Notes And Practical Tips

Keep a copy of your prescription and the PIL and carry a brief medicine card listing nifedipine (Coracten/Adalat) for outpatient appointments.

When starting or increasing dose, avoid risky activities until you are confident of your reaction.

Report suspected side effects to the MHRA Yellow Card scheme and keep your GP informed about any new symptoms or other medicines started.

For any urgent concerns such as chest pain or collapse, call 999 or present to A&E immediately.

Your community pharmacist can provide timely interaction checks, a counselling record and support with adherence and monitoring between GP visits.